Geron grants Janssen Biotech global rights to imetelstat; deal terminated
Just a couple weeks after the FDA removed a clinical hold on its modified oligonucleotide imetelstat, cancer-focused Geron Corp. licensed Janssen Biotech Inc. exclusive worldwide rights to develop and commercialize the telomerase inhibitor (GRN163L) for oncology indications, including myeloid malignancies, and all other human therapeutic uses. Janssen will pay $35mm up front initially, up to $900mm in development, regulatory, and commercial milestones, plus sales royalties.
- Antisense, Oligonucleotides
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.